Loading...

Media is loading
 

Date of Award

Spring 2020

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Amanda Seymour

Abstract

HER2 positive breast cancer is an aggressive disease, but since the introduction of the monoclonal antibody, trastuzumab, has had improved prognostic outcomes. Currently, trastuzumab is the standard of care in the adjuvant, or after surgery, regimen. New research has found that less recurrences occur if tumor regression is achieved prior to surgery, also known as pathological complete response (pCR). Examination into trastuzumab in the neoadjuvant, or prior to surgery, regimen has led to interest in determining the optimal setting of trastuzumab. This presentation analyzes recurrence outcomes in patients with early stage HER2 positive breast cancer that received neoadjuvant trastuzumab compared to adjuvant trastuzumab.

Additional Files

Poster Presentation.pptx (1202 kB)

Share

COinS
 

The recurrence outcomes of HER2+ Breast Cancer with trastuzumab in the neoadjuvant and adjuvant setting.

HER2 positive breast cancer is an aggressive disease, but since the introduction of the monoclonal antibody, trastuzumab, has had improved prognostic outcomes. Currently, trastuzumab is the standard of care in the adjuvant, or after surgery, regimen. New research has found that less recurrences occur if tumor regression is achieved prior to surgery, also known as pathological complete response (pCR). Examination into trastuzumab in the neoadjuvant, or prior to surgery, regimen has led to interest in determining the optimal setting of trastuzumab. This presentation analyzes recurrence outcomes in patients with early stage HER2 positive breast cancer that received neoadjuvant trastuzumab compared to adjuvant trastuzumab.